Supernus Pharmaceuticals to Participate in June Investor Conferences
Rhea-AI Summary
Supernus Pharmaceuticals (Nasdaq: SUPN) will participate in two June 2026 investor conferences focused on healthcare.
Management joins the Jefferies Global Healthcare Conference on June 3, 2026, including a webcasted fireside chat, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – SUPN
In the May 28 session, SUPN gained 0.45%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Investor conference | Neutral | +1.6% | Announced participation in Bank of America 2026 Health Care Conference. |
| May 05 | Earnings release | Positive | +4.6% | Reported Q1 2026 revenue growth and reiterated full-year guidance. |
| Apr 22 | Earnings date notice | Neutral | +0.2% | Announced timing of Q1 2026 results and conference call details. |
| Apr 20 | Board change | Positive | -4.2% | Peer Alpha Cognition appointed new director with significant industry experience. |
| Feb 24 | Earnings release | Positive | +5.7% | Reported record Q4 and FY 2025 revenues and issued 2026 guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings releases with strong growth have been followed by positive price reactions, while one positive governance event in a peer name coincided with a negative move, indicating occasional divergence.
Over the past several months, Supernus has highlighted multiple milestones. Earnings on Feb 24, 2026 and May 5, 2026 showed strong revenue growth and were followed by price gains of 5.67% and 4.59%. Conference participation notices on Apr 22 and May 6, 2026 had modest or small positive reactions. Today’s June conference participation fits this pattern of routine investor-relations updates following a period of strong reported financial performance.
Key Terms
central nervous system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences:
| 2026 Jefferies Global Healthcare Conference | |
| Date: Fireside chat: Place: Webcast Link: | Wednesday, June 3, 2026 10:30 a.m. ET Marriott Marquis, New York, NY Here |
| Goldman Sachs 47th Annual Global Healthcare Conference | |
| Date: Place: | Monday, June 8, 2026 Loews Miami Beach, Miami Beach, Fla. |
Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.
A live audio webcast of the Jefferies Global Healthcare Conference can also be accessed on the Events & Presentations section of the Supernus Pharmaceuticals website at www.supernus.com. Archived replays of the webcast will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; the Company's ability to increase its net revenue from its products, and the products of its subsidiaries; the Company's ability to commercialize its products, and the products of its subsidiaries; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
